Health TrialsbyHealthPanel

Pulmonary Vascular Disease and Cardiac Performance in Extreme Preterm Infants

ConditionPrematurity; Extreme
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age7-5
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

About this trial

Pulmonary vascular disease and cardiac performance in extreme preterm infants: A prospective cross-sectional study

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Infants born at <29 weeks' gestational age admitted to the NICU

All infants born at <29 weeks' gestational age followed at MCH clinic after an admission in the NICU for prematurity <29 weeks

Disqualifiers

Congenital heart disease (except an atrial (ASD) or ventricular septal defect (VSD), or a patent ductus arteriosus (PDA))

Congenital severe lung or airway malformation (choanal atresia, trachea-esophageal fistula or congenital pulmonary airway malformation)

Genetic disorder (Trisomy 21).

Trial population

Extreme premature newborns (\<29 weeks)

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Echocardiography

    Other intervention

    Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures

Treatment groups

150 Participants
are divided into 3 treatment groups
Group A: Neonatal profile1 intervention
Group B: Infant profile ( between 4 months and 9 months)1 intervention
Group C: Pediatric profile (36 months and 5 years)1 intervention

Trial outcomes

Primary outcomes

1

Heart function by echocardiography

STE allows for calculation of strain (absolute deformation) of segmental areas of the heart to provide insight on cardiac performance

Time frame
7-10 days of chronological age
2

Heart function by echocardiography

STE allows for calculation of strain (absolute deformation) of segmental areas of the heart to provide insight on cardiac performance

Time frame
35-37 weeks post-menstrual age
3

Heart function by echocardiography

STE allows for calculation of strain (absolute deformation) of segmental areas of the heart to provide insight on cardiac performance

Time frame
39-44 weeks PMA
4

Heart function by echocardiography

STE allows for calculation of strain (absolute deformation) of segmental areas of the heart to provide insight on cardiac performance

Time frame
4 months PMA

Secondary outcomes

1

Neuro-developmental profile

Neuro-developmental profile of these patients at individual time points and put this profile in context of their cardiac performance by echocardiography

Time frame
7-10 days of chronological age
2

Neuro-developmental profile

Neuro-developmental profile of these patients at individual time points and put this profile in context of their cardiac performance by echocardiography

Time frame
35-37 weeks post-menstrual age
3

Neuro-developmental profile

Neuro-developmental profile of these patients at individual time points and put this profile in context of their cardiac performance by echocardiography

Time frame
39-44 weeks PMA
4

Neuro-developmental profile

Neuro-developmental profile of these patients at individual time points and put this profile in context of their cardiac performance by echocardiography

Time frame
4 months PMA

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

McGill University Health Centre/Research Institute of the McGill University Health Centre

Lead sponsor

Source ClinicalTrials.gov
Apply now